Comparative Pharmacology
Head-to-head clinical analysis: DESONATE versus PSORCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESONATE versus PSORCON.
DESONATE vs PSORCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
None Documented
None Documented
Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing.
Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%).
Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid